New drug combo shows promise for tough stomach cancer
Disease control
Completed
This study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…
Phase: PHASE2 • Sponsor: Genome & Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC